An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

April 30, 2026

Conditions

Prostatic Adenocarcinoma

Interventions

DRUG

Enzalutamide

enzalutamide 160 mg PO daily

Trial Locations (1)

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER